Cancer Research SABCS  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 67, 11218, December 1, 2007. doi: 10.1158/0008-5472.CAN-07-0922
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sasaki, C. Y.
Right arrow Articles by Longo, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sasaki, C. Y.
Right arrow Articles by Longo, D. L.

Molecular Biology, Pathobiology, and Genetics

Traf1 Induction and Protection from Tumor Necrosis Factor by Nuclear Factor-{kappa}B p65 Is Independent of Serine 536 Phosphorylation

Carl Y. Sasaki, Colin F. Slemenda, Paritosh Ghosh, Theresa J. Barberi and Dan L. Longo

Laboratory of Immunology, National Institute on Aging, Baltimore, Maryland

Requests for reprints: Carl Y. Sasaki, Laboratory of Immunology, National Institute on Aging, 5600 Nathan Shock Drive, Baltimore, MD 21224. Phone: 410-558-8096; Fax: 410-558-8284; E-mail: sasakic{at}grc.nia.nih.gov.

Abnormal nuclear factor-{kappa}B (NF-{kappa}B) signaling has been attributed to the initiation and progression of cancer. Posttranslational modification of p65 facilitates optimal NF-{kappa}B signaling after activation. Here, we show that the phosphorylation of serine 536 was required for p65-mediated transcription and I{kappa}B{alpha} expression in fibroblasts. Furthermore, tumor necrosis factor (TNF) treatment slightly induced p65 phosphorylation, and both unphosphorylated and phosphorylated p65 translocated into the nucleus. The phosphorylation of serine 536 was not required for p65-mediated protection from TNF cytotoxicity and Traf1 induction in fibroblasts. Also, the corecruitment of p65 and RNA polymerase II to the Traf1 enhancer region did not require p65 phosphorylation. However, the corecruitment of p65 and RNA polymerase II to the Csf2 promoter required the phosphorylation of serine 536. These findings suggested that the requirement of serine phosphorylation at residue 536 and the distance between the NF-{kappa}B response element and the start of transcription may influence which genes will be transcribed. [Cancer Res 2007;67(23):11218–25]







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.